Filing Details
- Accession Number:
- 0001140361-10-044135
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-11-08 13:42:36
- Reporting Period:
- 2010-11-04
- Filing Date:
- 2010-11-08
- Accepted Time:
- 2010-11-08 13:42:36
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1350577 | Ali Naqui | One Idexx Drive Westbrook ME 04092 | Corporate Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2010-11-04 | 3,770 | $25.45 | 18,778 | No | 4 | M | Direct | |
Common Stock | Disposition | 2010-11-04 | 2,770 | $61.50 | 16,008 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Incentive Stock Option | Disposition | 2010-11-04 | 3,770 | $0.00 | 3,770 | $25.45 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2014-02-04 | No | 4 | M | Direct |
Footnotes
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $61.43 to $61.64, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of options to buy shares of common stock becomes exercisable as to 1,370 shares on 2/5/2008 and the remaining 2,400 shares on 2/5/2009.